ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection

Epidemiology, risk factors, pathogenesis, and natural history of thoracic aortic aneurysm and dissection
Literature review current through: Jan 2024.
This topic last updated: Apr 18, 2023.

INTRODUCTION — It is important to have a working knowledge of the risk factors, pathophysiology, and natural history of thoracic aortic aneurysm and dissection (TAAD) to aid with clinical decision making. Most thoracic aortic aneurysms (TAAs) identified in patients over age 65 years are degenerative and share many of the same risk factors as abdominal aortic aneurysm (AAA); inflammatory disorders such as giant cell arteritis are also associated with TAA, primarily in this age group. TAAD occurring in patients younger than 65 years is more often associated with a genetic predisposition that can be familial or related to defined genetic disorders such as Marfan syndrome. Approximately 25 percent of patients with TAA will also be found to have an AAA [1-3].

The natural history of TAA is one of slow expansion with a progressive increase in the risk of aortic dissection at larger aortic sizes. The rate of aortic expansion depends upon aneurysm etiology, diameter, and location. Expansion rates for TAA are generally less than those of AAA. In addition, the generally slow expansion of TAA means that most patients with TAA are asymptomatic and many patients will succumb to other disease processes without being aware that TAA is present. TAA that produces symptoms are typically very large and at risk for rupture, which is associated with high rates of morbidity and mortality.

This topic will review the etiology, risk factors, pathogenesis, and natural history of TAAD. The clinical features, diagnosis, and management of thoracic aortic aneurysm, including surgical and endovascular repair, are discussed elsewhere. (See "Clinical manifestations and diagnosis of thoracic aortic aneurysm" and "Management of thoracic aortic aneurysm in adults" and "Overview of open surgical repair of the thoracic aorta" and "Endovascular repair of the thoracic aorta".)

DEFINITION AND CLASSIFICATION — A true aneurysm is defined as a segmental, full-thickness dilation of a blood vessel having at least a 50 percent increase in diameter compared with the expected normal diameter [4-6]. The normal diameter of the thoracic aorta varies with location and age. Normal average diameters are discussed separately. (See "Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Definition of TAA'.)

Pseudoaneurysm (false aneurysm) represents a collection of blood and connective tissue outside the aortic wall, which in the thoracic aorta can result from a contained aortic rupture or from a variety of pathologic processes such as penetrating aortic ulcer, aortic dissection, trauma, or other acute aortic syndromes. These disorders are discussed elsewhere. (See "Overview of acute aortic dissection and other acute aortic syndromes" and "Clinical features and diagnosis of blunt thoracic aortic injury" and "Overview of acute aortic dissection and other acute aortic syndromes", section on 'Definition and pathophysiology'.)

TAA and TAAD are classified by location within the aorta (ascending aorta, aortic arch, descending aorta (figure 1)), extent of aortic involvement, and morphology [5]. These categories help to stratify the approach to management. (See "Clinical manifestations and diagnosis of thoracic aortic aneurysm", section on 'Classification' and "Overview of acute aortic dissection and other acute aortic syndromes", section on 'Classification' and "Management of chronic type B aortic dissection", section on 'Classification'.)

EPIDEMIOLOGY — It is difficult to assess the prevalence and incidence of TAA because TAA is a clinically silent disease. Fatalities due to TAA complications (rupture, dissection) are likely to be attributed to other causes, such as acute myocardial infarction, in those who do not undergo postmortem examination [5]. In a study from Japan, type A aortic dissection was found in 7 percent of patients that received postmortem computed tomography (CT) scans after presenting with an out-of-hospital cardiac arrest [7]. One population study that used chest CT to screen for other conditions estimated the prevalence of asymptomatic TAA at 0.16 percent [8]. Another study that sought to better define what constitutes a "normal" aorta found a prevalence of 0.34 percent [9]. However, these studies likely underestimate the prevalence of asymptomatic TAA in the general population since TAA was defined as aortic diameter >5 cm; thus, TAAs between 4 and 5 cm were not included.

In two separate studies, the annual incidence of TAA was estimated to be 5.6 and 10.4 cases per 100,000 patient-years [2,3]. The incidence of TAA appears to be increasing, though it is difficult to determine if this is related to increased detection through imaging or a true increase possibly related to the aging population [10]. In studies performed where the population is stable and postmortem examinations are performed routinely, there appears to be a real increase in the incidence of TAA over the past several decades [3,10-12]. The incidence of ruptured TAA also appears to be increasing [13].

Thoracic aneurysms occur most commonly in the sixth and seventh decade of life and affect males approximately two to four times more commonly than females.

ETIOLOGY AND RISK FACTORS — Most thoracic aortic aneurysms (TAAs) are degenerative (also termed idiopathic or sporadic) and occur in association with risk factors for atherosclerosis. On occasion, a broad group of disorders classified under aortitis can also cause TAA in response to a systemic autoimmune process [14,15]. TAA may also be acquired as a result of aortic infection.

TAA frequently occurs as a manifestation of known connective tissue disorders such as the Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes (syndromic TAA). However, it has been estimated that as many as one-fifth of patients with a TAA have a family history of aneurysmal disease independent of known genetic syndromes (ie, nonsyndromic TAA) [16].

At risk for atherosclerosis — The majority of thoracic aortic aneurysms are degenerative and occur in association with risk factors for atherosclerosis such as smoking, hypertension, and hypercholesterolemia [17,18]; however, it remains unclear what role atherosclerosis plays in aneurysm formation [18,19]. (See 'Pathogenesis' below.)

Hypertension is an important risk factor that is present in over 60 percent of patients with TAA [2]. In the Hypertension Genetic Epidemiology Network (HyperGEN) study, the estimated prevalence of aortic root dilation was 4.6 percent and was not significantly different between those with or without hypertension; however, most patients with hypertension were receiving antihypertensive therapy [3,20].

Although diabetes is associated with atherosclerosis, diabetes is negatively correlated with TAA, similar to abdominal aortic aneurysm [21].

Presence of other aneurysms — Aneurysms of the large arteries are diagnosed in up to 13 percent of patients with TAA; approximately 20 to 25 percent of patients with a large thoracic aortic aneurysm also have an abdominal aortic aneurysm (AAA) [1,2,22]. Conversely, in patients with known AAA, a study of 1305 patients found a high prevalence of dilatation/aneurysm of the ascending aorta and the aortic arch evaluated by transthoracic echocardiography [23]. Using sex-specific criteria for aneurysm, 4 percent of the patients being evaluated prior to AAA repair had an ascending aortic aneurysm and 6.5 percent had an aortic arch aneurysm. Furthermore, 2 percent of men had an ascending aortic aneurysm compared with 25.8 percent of the women, and 6.6 percent of men had an aortic arch aneurysm compared with 10.5 percent of the women. This study excluded patients with other risk factors for the development of ascending TAA such as bicuspid aortic valve, previous aortic surgery, and other genetic syndromes. (See "Clinical features and diagnosis of abdominal aortic aneurysm".)

Thoracic aneurysm and cerebral aneurysms can also coexist [24-26]. One radiologic study of 212 patients with a TAA who had undergone concurrent brain imaging for clinical reasons found intracranial aneurysms in 9 percent of patients, with a higher prevalence of cerebral aneurysm in patients with a descending versus ascending TAA [24]. Patients with bicuspid aortic valve, a known risk factor for TAA, have an increased risk for developing intracranial aneurysm compared with the normal population [26]. Screening for brain aneurysm is also generally recommended in patients with nonsyndromic familial TAA. (See "Screening for intracranial aneurysm" and "Management of thoracic aortic aneurysm in adults", section on 'Identifying associated aneurysm'.)

Prior aortic dissection — Acute aortic dissection often involves the ascending and descending thoracic aorta. For patients who do not require immediate operation and survive an acute aortic dissection, aneurysmal degeneration leading to progressive aortic expansion and late aortic rupture can occur [27]. Although not a true aneurysm because the aortic wall is not full thickness in the dissected segment, this condition is frequently referred to as a "dissecting aneurysm" or "aneurysmal dissection." Predictors of these complications include male sex, age of <60 years, type B aortic dissection, Marfan syndrome, an initial postoperative aortic diameter of ≥40 mm, the presence of blood in the false lumen, a large false lumen, the size and location of the intimal tear, elevated systolic blood pressure, and elevated pulse pressure [28]. (See "Clinical features and diagnosis of acute aortic dissection" and "Management of chronic type B aortic dissection", section on 'Natural history'.)

Chest trauma — Chest trauma is more likely to lead to a pseudoaneurysm of the descending thoracic aorta at the aortic isthmus due to deceleration forces rather than a true full-thickness aneurysm. Blunt aortic injury is discussed in detail elsewhere. (See "Clinical features and diagnosis of blunt thoracic aortic injury", section on 'Mechanism of injury' and "Clinical features and diagnosis of blunt thoracic aortic injury", section on 'Aortic injury grading'.)

Aortitis — Aortitis refers to inflammation of the aortic wall, which can be due to infectious or inflammatory etiologies. Aortitis as a cause of TAA is overall rare.

Infectious — Infection of the thoracic aorta leading to aneurysm is most commonly due to septic embolism, but direct bacterial inoculation, bacteremic seeding, and contiguous infection can also occur. The infection weakens the constituents of the aortic wall, leading to rapid aneurysm formation. These aneurysms are commonly associated with penetrating aortic ulcers and many times form saccular aneurysms. The etiology and clinical features of infected (mycotic) aneurysms are reviewed separately. (See "Overview of infected (mycotic) arterial aneurysm" and "Overview of acute aortic dissection and other acute aortic syndromes", section on 'Penetrating aortic ulcer'.)

Inflammatory disorders — A broad group of inflammatory disorders are associated with the development of TAA, including giant cell arteritis, Takayasu arteritis, IgG4-related disease, rheumatoid arthritis, ankylosing spondylitis, granulomatosis with polyangiitis, reactive arthritis, and Behcet syndrome.

Giant cell arteritis is the most common inflammatory disorder leading to TAA formation. Thoracic aortic disease manifesting as thoracic aortic aneurysm or aortic dissection will develop in as many as 11 percent of patients with giant cell arteritis [29]. TAA is usually a late manifestation occurring in patients who had been previously treated a number of years [30]. The initial clue to the diagnosis may be based on pathologic review of the explanted aortic tissue. (See "Clinical manifestations of giant cell arteritis", section on 'Large vessel involvement'.)

In one prospective study, among 788 patients requiring surgery for thoracic aortic disease (aneurysm or dissection), 39 (4.9 percent) were due to histologically proven aortitis [31]. The distribution of etiologies in the patients with an inflammatory cause was as follows:

Takayasu/giant cell aortitis (n = 31)

Inflammatory aneurysm (n = 3)

Nonspecific lymphoplasmacellular aortitis (n = 2)

Systemic lupus erythematosus aortitis (n = 1)

Behçet syndrome (n = 1)

In a separate review of pathology specimens from 684 patients who underwent surgical repair of ascending thoracic aortic aneurysm, aortitis was identified in 47 (6.9 percent) [32]. Among these, 32 of the cases of aortitis were deemed idiopathic. Aortic aneurysms associated with idiopathic aortitis are reported to be limited to the thoracic aorta in >90 percent of patients [32-34].

Genetic predisposition — Genetic defects that lead to abnormalities in connective tissue structure and function predispose to TAAD [35-44]. Genetically mediated TAA accounts for approximately 5 percent of TAAs. Approximately 20 percent of patients with a TAAD have a family history of aneurysmal disease that is independent of any known genetic tissue syndrome (nonsyndromic TAAD) [16,45]. A strong personal or family history of dissection or aneurysm (particularly type A) in young (<50 years old) individual may be an indication for genetic testing for inherited aortopathy [46]. (See "Management of thoracic aortic aneurysm in adults", section on 'Identifying associated genetic conditions'.)

Syndromic connective tissue disorders — Genetic syndromes (syndromic TAAD), such as Marfan syndrome, vascular Ehlers Danlos syndrome, Loeys-Dietz syndrome, and Turner syndrome, have more aggressive rates of aortic expansion and are more likely than degenerative TAA to require intervention. Furthermore, if a patient with an underlying connective tissue disorder undergoes intervention for a type A aortic dissection as his/her index aortic operation, those portions of the aorta with residual chronic dissection in the more distal aorta are at very high risk for degeneration to thoracoabdominal aortic aneurysm and must undergo postoperative surveillance. (See "Overview of open surgical repair of the thoracic aorta", section on 'Follow-up imaging'.)

Marfan syndrome — The Marfan syndrome (table 1) is associated with mutations in the FBN-1 gene. The aneurysm in Marfan syndrome is typically located in the aortic root but may extend to the ascending aorta. These aneurysms are associated with accelerated expansion compared with degenerative aneurysms and a high risk of aortic complications at a relatively young age [5,47-49]. Aortic root dilatation, aortic regurgitation, and aortic dissection are the main causes of morbidity and mortality in patients with Marfan syndrome [50]. Marfan syndrome is discussed in detail elsewhere. (See "Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders" and "Heritable thoracic aortic diseases: Pregnancy and postpartum care" and "Management of Marfan syndrome and related disorders".)

Vascular Ehlers-Danlos syndrome — Vascular Ehlers-Danlos syndrome is a group of conditions due to defects in type III procollagen that cause hyperelasticity and fragility of the skin and hypermobility of the joints. Most types of Ehlers-Danlos are not associated with aortic dilation, although mild mitral valve prolapse is often present. However, in the vascular type (previously type IV) Ehlers-Danlos syndrome, vascular and connective tissue integrity is markedly impaired and spontaneous rupture of large and medium-sized arteries can occur [51]. (See "Clinical manifestations and diagnosis of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder", section on 'Differential diagnosis'.)

Loeys-Dietz syndromes — Loeys-Dietz syndrome (LDS) is an autosomal dominant condition that may phenotypically resemble Marfan syndrome and is characterized by a high risk for aneurysm and dissection throughout the arterial tree at a young age [5,37,52,53]. LDS is caused by heterozygous missense mutations in either TGF-B receptor gene (TGFBR1 [LDS-1] or TGFBR2 [LDS-2]) or mutations within the TGF-B pathways, including SMAD-2, SMAD-3 (LDS-3), and PMEPA1 [35,37,54]. (See "Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders", section on 'Differential diagnosis' and "Management of thoracic aortic aneurysm in adults".)

Turner syndrome — Turner syndrome is a gonadal dysgenesis syndrome characterized by a 45X female with ovarian failure and characteristic features such as a webbed neck, short stature, and low-set ears. Congenital heart defects, diabetes, and hypothyroidism are also associated with the syndrome. Approximately 10 to 25 percent of patients have bicuspid aortic valves, 8 percent will have coarctation, and approximately 33 percent will have aortic dilatation. Most Turner syndrome patients who develop aortic dissection have bicuspid valves, coarctation, or risk factors like hypertension. Although Turner syndrome patients have an increased risk of aortic dissection compared with the normal population, this risk is viewed to be much lower compared with Marfan syndrome or Loeys-Dietz syndrome [55,56]. (See "Clinical manifestations and diagnosis of Turner syndrome".)

Nonsyndromic disorders — Patients who have thoracic aortic disease but who do not meet strict criteria for known connective tissue syndromes are grouped as nonsyndromic. The most common of these is likely familial TAAD, for which clinical studies have found a strong genetic component [16,57]. Genetically mediated conditions present at birth can also predispose to thoracic aortic aneurysm later in life, such as bicuspid aortic valve [58-61].

Familial TAAD — Familial TAAD refers to patients who have thoracic aortic disease associated with a family history of aneurysmal disease but who do not meet strict criteria for known connective tissue syndromes. Familial TAAD is increasingly being recognized and can include patients with a dilated aorta or aneurysm affecting other vessels, and a family history of dissection, rupture, or sudden unexplained death. The ascending thoracic aorta is involved in approximately 80 percent and the descending aorta is affected in the remaining 20 percent [15]. Patients with familial TAAD generally present at an earlier age (56.8 years) compared with patients with degenerative TAA (57 versus 64 years in one study) and also have faster rates of aortic expansion [16]. (See 'Natural history' below and "Management of thoracic aortic aneurysm in adults", section on 'Diameter criteria'.)

Increased aortic diameter, which clusters in families, appears to be a precursor of aortic aneurysm and a risk factor for dissection. In a review of data from the Framingham Heart Study, 235 children of participants had a multivariable-adjusted, approximately three-fold increased likelihood of having an aortic diameter in upper quartile of sex- and age-standardized aortic size if they had parent(s) in the upper quartile [62]. To estimate the risk for developing aortic aneurysm among family members, the investigators also analyzed data from the national database from Denmark. Compared with matched controls, the risk for aortic aneurysm was significantly increased for first-degree relatives of patients with aortic aneurysm and dissection (hazard ratio [HR] aneurysm: 6.70, 95% CI 5.96-7.52; HR dissection: 9.24, 95% CI 5.53-15.44). These estimates remained unchanged on adjusting for several comorbidities, including prevalent hypertension, bicuspid aortic valve, and the Marfan syndrome. In addition to the typical limitations of database studies, it has been noted that the calculated rates of aneurysm and dissection in family members are higher than in prior studies, which may be related to the inclusion of both thoracic and abdominal aortic aneurysms. The authors also measured the aorta in a single dimension at fixed anatomic sites, rather than the largest maximal aortic dilation (any dimension) in an aortic zone.

Studies of the family trees of patients with isolated TAA or dissection have found that 21 percent of proband have at least one family member with a known arterial aneurysm [16,57]. The rate of inheritance may be higher, since many family members may not be aware that an aneurysm is present. Approximately 80 percent of familial TAAs appear to be inherited in an autosomal-dominant manner, but other genetic patterns are also expressed [16,57]. The variable penetrance and expression of the genetic mutations make obtaining a definitive diagnosis difficult [42,43]. Mutations in the transforming growth factor beta receptor 2 gene (TGFBR2) may be responsible for approximately 5 percent of familial cases [41,63,64]. Other mutations include ACTA2 and MYH11 [5]. ACTA2 may account for up to 14 percent of genetic mutations associated with familial syndromes. Each year, new gene mutations are identified in families with familial TAAD. It is therefore suggested that patients with familial TAAD without an identified gene mutation be reassessed by a genetic specialist periodically.

The location of the TAA in the proband closely mirrors aneurysm location in family members [57], supporting the notion that the etiology of aneurysmal disease is differentiated proximal and distal to the ligamentum arteriosum. Disease proximal to the ligament is predominantly nonatherosclerotic in nature, whereas disease distal to it is strongly associated with atherosclerosis [10].

Bicuspid aortic valve — There is an association between bicuspid aortic valve, which is the most commonly recognized congenital abnormality in adulthood, and thoracic aortic aneurysm/dissection [65,66]. A heritable tendency, likely autosomal dominant, is supported by family studies that have identified features of aortopathy in otherwise normal (ie, three-leaflet valve) first-degree relatives of patients with bicuspid aortic valves [5,65,67-70]. Aortopathy is most commonly seen is the ascending segment, but aortic root aneurysms may also be observed. The prevalence of aortic pathology among those with bicuspid aortic valve is discussed in detail separately. (See "Clinical manifestations and diagnosis of bicuspid aortic valve in adults", section on 'Aortic dilation and aortic dissection'.)

Aneurysm-osteoarthritis syndrome — Aneurysm osteoarthritis syndrome, caused by pathogenic variants of "mothers against decapentaplegic homolog 3" (SMAD3), is a recently described autosomal dominant syndrome characterized by aneurysms and arterial tortuosity that may occur in combination with early-onset osteoarthritis [71,72]. Aneurysms are most frequently localized to the aortic root but can be found throughout the arterial tree, including the iliac, visceral, and intracranial arteries [72]. In one review of 38 patients, 71 percent had aortic root dilation [73].

PATHOGENESIS — Aortic disease distal to the ligamentum arteriosum is predominantly strongly associated with atherosclerosis, whereas aortic disease proximal to it is predominately nonatherosclerotic in nature [10]. These differences may be related to the differing embryologic origins of ascending aorta and descending aorta smooth muscle cells (SMCs), which are responsible for secreting many of the proteolytic factors implicated in aneurysm formation. The ascending aorta and great vessel SMCs arise from neural crest cells, whereas the descending aorta arises from paraxial mesoderm [74,75]. The aortic valve arises from the lateral plate mesoderm [74]. Abnormalities of the aortic valve (eg, bicuspid aortic valve) are highly associated with coarctation of the aorta, suggesting that the abnormal aortic tissue may extend into the distal arch or the proximal descending aorta [76].

Most thoracic aortic aneurysms (TAAs) are degenerative, resulting from alterations in vascular wall biology that lead to loss of structural integrity and aortic wall strength [17,19,77]. The underlying triggers for degenerative TAA are not known for certain, but similar processes appear to be responsible for degenerative abdominal aortic aneurysm (AAA). The combination of protein degradation and mechanical factors are thought to cause medial degeneration, which has the appearance of smooth muscle cell necrosis and elastic fiber degeneration with cystic spaces in the media filled with mucoid material [78]. Cystic medial degeneration of the aorta occurs normally with aging but is accentuated by hypertension and other factors.

Most theories emphasize the primary role of breakdown of extracellular matrix proteins (ie, elastin and collagen) by proteases such as elastase, collagenase, various matrix metalloproteinases (MMPs) [79-81], and plasmin [82]. These proteolytic factors are derived from endothelial and smooth muscle cells and also from inflammatory cells infiltrating the media and adventitia [82]. The following observations in animal models are consistent with the importance of plasmin and MMPs in aortic aneurysm formation:

Blockade of plasmin formation by overexpression of plasminogen activator inhibitor-1 prevents the formation of aneurysms and rupture by inhibiting metalloproteinase activation [83].

Aneurysm rupture correlates with an increase in metalloproteinase (gelatinase A and B) levels; local overexpression of tissue inhibitor of matrix metalloproteinases, produced by retrovirus-infected smooth muscle cells, can prevent aneurysmal degeneration and rupture [84].

Familial TAA and TAA associated with genetic syndromes share similar pathogenic pathways with degenerative aneurysms, but with some unique differences related to the known genetic defects [85-87]. Specifically [85]:

The ACTA2 gene encodes a protein called smooth muscle alpha (α)-2 actin, which is part of the actin protein family. Deficiency in patients with familial TAA leads to decreased numbers and disorganization of vascular smooth muscle cells [88].

The TGFBR1 gene encodes a protein called transforming growth factor-beta (TGF-B) receptor type 1, which transduces signals from the cell surface into the cell. There are five different putative mutations associated with Loeys-Dietz syndrome with the common theme of TGF-B dysregulation. Mutations that cause LDS are predicted to diminish TGF-B signaling; however, aortic surgical samples show evidence of paradoxically increased TGF-B signaling [37]. This would seem to indicate that other, unknown mechanisms compensate for the lack of receptor activity. This overactivity disrupts connective tissue development.

The TGFBR2 gene encodes a protein called transforming growth factor-beta (TGF-B) receptor type 2, which transduces signals from the cell surface into the cell. The pathogenetic mechanism is similar to TGFBR1 as described above. More than 70 mutations in the TGFBR2 gene have been found to cause the Marfan syndrome and Loeys-Dietz syndrome types. At least two TGFBR2 gene mutations have been identified in people with familial thoracic aortic aneurysm.

The FBN1 gene encodes for a large protein called fibrillin-1, which is transported out of cells into the extracellular matrix. More than 1000 FBN1 gene mutations have been identified in Marfan syndrome. Most of these mutations alter a single amino acid in the fibrillin-1 protein, reducing the amount of fibrillin-1 produced by the cell, altering the structure or stability of fibrillin-1, or impairing the transport of fibrillin-1 out of the cell. These mutations lead to a severe reduction in the amount of fibrillin-1 available to form microfibrils. Without enough microfibrils, TGF-B becomes dysregulated, leading to alterations in aortic wall homeostasis.

NATURAL HISTORY — The natural history of aneurysm is one of slow expansion with a progressive increase in the risk of aortic dissection at larger aortic sizes. The rate of aortic expansion depends upon aneurysm etiology, diameter, and location. Expansion rates for TAA are generally less than those of AAA. In addition, the generally slow expansion of TAA means that most patients with TAA are asymptomatic, and many patients will succumb to other disease processes without being aware that TAA is present. Aneurysms that do produce symptoms are typically very large and at risk for rupture, which is associated with high rates of morbidity and mortality.

The natural history of TAA is one of slow expansion with an increasing risk of sudden aortic dissection as the aorta enlarges. Expansion rates range from 0.1 to 1.0 cm per year, depending upon TAA etiology, diameter, and location within the aorta [10,89-95]. Although rapid expansion can occur in a TAA, most reports of rapid growth usually reflect measurement errors; however, when rapid expansion is seen, it raises concern for aortic dissection or aortic infection [10].

Expansion — In general, isolated degenerative ascending aortic aneurysms have an average expansion rate of 0.1 cm per year, whereas descending TAAs expand by approximately 0.3 cm per year [16,96]. Patients with familial TAAs have faster average rates of expansion at 0.2 cm per year (combined ascending and descending TAA) compared with patients with degenerative TAAs [57]. TAA associated with genetic syndromes can expand more rapidly. Aneurysms associated with bicuspid aortic valve have average expansion rates of up to 0.2 cm per year [65,97,98]. Marfan syndrome is associated with average expansion rates up to 0.3 cm per year. TAAs associated with the particularly aggressive Loeys-Dietz syndrome can expand very rapidly at up to 1.0 cm per year [52,57]. (See 'Genetic predisposition' above.)

Similar to abdominal aortic aneurysm, larger-diameter TAA expands more rapidly than smaller-diameter TAAs [16]. This was illustrated in a study of 67 patients with thoracic aortic aneurysm who underwent serial computed tomography (CT) imaging [95]. The rate of expansion for aneurysms >5.0 cm in diameter was approximately 0.8 cm per year, but approximately 0.2 cm per year for aneurysms <5.0 cm. A history of hypertension did not affect the rate of aneurysm expansion. However, these studies are older, and the location and specific etiology of the aneurysm may not have been taken into account.

The anatomic location of the aneurysm is another factor associated with the rate of expansion. In a series of 87 patients who underwent serial CT or magnetic resonance (MR) imaging, aneurysms located within the middescending aorta showed the most rapid expansion, while those in the ascending aorta had the slowest rate, despite having a larger initial diameter [94].

Aneurysm morphology, specifically saccular versus fusiform, is thought to increase expansion rates and rupture risk. Saccular aneurysms are associated with aortic infection and as such are often treated more aggressively. In a review of 153 saccular aneurysms, 2 were in the ascending aorta, 23 were in the aortic arch, and 219 were in the descending thoracic aorta [99]. The expansion rate of saccular aneurysms that were conservatively managed was 0.28 cm±0.29 cm/year. (See "Overview of infected (mycotic) arterial aneurysm".)

Rupture/dissection — The risk of complications of TAA (rupture, dissection) increases with larger aortic diameter. In several series, aneurysm rupture occurred in 32 to 68 percent of medically treated patients and accounted for 32 to 47 percent of deaths [2,100-103]. The one-, three-, and five-year survival rates of unoperated thoracic aneurysms were 65, 36, and 20 percent, respectively. Concomitant cardiovascular disease is the second most common cause of death in these patients.

The most important determinant of rupture is the diameter of the aneurysm and the underlying cause [3,104-109]. Other factors, such as the presence of acute symptoms, a concomitant bicuspid aortic valve, a connective tissue disease, or a rapidly expanding aortic diameter also increase the risk for rupture [110]. Hypertension also plays a critical role in both aneurysmal expansion as well as progression to acute aortic syndrome. An extreme example of this is TAAD related to methamphetamine abuse. Therefore, a comprehensive social history and toxicology screen is essential upon diagnosis.

The annual risk of rupture or dissection is <2 percent for TAAs between 4.0 and 4.9 cm but nearly 7 percent for TAAs >6.0 cm [93]. There is a significant increase in the risk of rupture or dissection for a diameter greater than 6.0 cm for an ascending TAA and 7.0 cm for a descending TAA [111]. In another series of 370 patients, the median diameter at the time of rupture or dissection was 5.9 cm for ascending aneurysms and 7.2 cm for descending aneurysms [105]. It is important to note that the ascending aorta expands by an average of 7 mm at the moment an aortic dissection occurs [112].

One group has shown that the clinical threshold for rupture mirrors the innate physical limits of the aortic wall. As the aorta approaches 6.0 cm, its distensibility rapidly falls [113]. At this diameter, the aorta loses its natural elasticity and effectively becomes a rigid tube. At a blood pressure of 200 mmHg, easily achieved through strenuous exercise or emotional distress, the stress generated in the wall of a 6.0-cm aorta can attain or exceed the maximum tensile strength of aortic tissue [113]. The traditional treatment threshold of an ascending diameter of 5.5 cm or greater was based off the concept of an aortic "hinge point" around 5.75 cm diameter whereby a significant increase in the risk of complications occurs. However, data using the same database have found a second "hinge point" at 5.25 cm [114]. This finding has led some to believe that treatment guidelines may need to be revisited and possibly shifted to lower diameters. (See "Management of thoracic aortic aneurysm in adults", section on 'Indications for repair'.)

Even though the risk of dissection/rupture increases with aortic diameter, most patients who present with dissection have smaller aneurysms, probably because many more individuals in the population with thoracic aortic aneurysm have thoracic aortic diameters between 4.0 and 5.5 cm, which have a low risk for rupture. In a review of 591 patients with type A dissection enrolled in the International Registry of Acute Aortic Dissection (IRAD), the mean diameter was 5.3 cm. Nearly 60 percent of patients had aortic diameter<5.5 cm, and 40 percent had aortic diameter <5.0 cm [115].

Fluoroquinolones have non-antimicrobial properties that may compromise the integrity of the vascular wall. Observational studies have suggested that fluoroquinolone use may be associated with an increased risk of aortic aneurysm or dissection. This issue is discussed in more detail separately. (See "Epidemiology, risk factors, pathogenesis, and natural history of abdominal aortic aneurysm", section on 'Fluoroquinolones and other antimicrobials used to treat infection'.)

SUMMARY AND RECOMMENDATIONS

A thoracic aortic aneurysm (TAA) is defined as a permanent localized dilation of the thoracic aorta, having at least a 50 percent increase in diameter compared with the expected normal diameter for that aortic segment. True aneurysms include all three layers of the vessel, including the intima, media, and adventitia. A pseudoaneurysm, or false aneurysm, is a collection of blood and connective tissue outside the aortic wall, usually the result of a focal rupture. Aneurysmal expansion can also occur in a segment of the aorta that has been involved in acute aortic dissection. (See 'Introduction' above and 'Natural history' above.)

Aortic aneurysm and aortic dissection are classified by the segment of the aorta that is involved. (See 'Definition and classification' above.)

The incidence of TAA is estimated to be 6 to 10 cases per 100,000 patient-years. TAA is more common in men. The majority of TAAs are degenerative and associated with risk factors similar for atherosclerosis (eg, hypertension, hypercholesterolemia, smoking). TAA is also associated with inflammatory disorders/vasculitis (eg, giant cell arteritis, Takayasu's aortitis), aortic infection (mycotic aneurysm), bicuspid aortic valve disease, and inherited connective tissue disorders such as Marfan, Loeys-Dietz, or vascular type Ehlers-Danlos syndromes. There are also familial associations with thoracic aneurysms, and it has been estimated that as many as 21 percent of patients with a thoracic aortic aneurysm/dissection (TAAD) have a family history of this disorder independent of those with Marfan syndrome or a bicuspid aortic valve. (See 'Epidemiology' above and 'Etiology and risk factors' above.)

Most TAADs result from alterations that lead to loss of structural integrity and aortic wall strength. A combination of breakdown of extracellular matrix proteins and mechanical factors are thought to cause medial degeneration, which occurs normally with aging but is accentuated by hypertension and other factors. Most theories emphasize the primary role of breakdown of the extracellular matrix proteins elastin and collagen by proteases such as collagenase, elastase, various matrix metalloproteinases, and plasmin (formed from plasminogen by urokinase plasminogen activator and tissue type plasminogen activator). Additional pathogenetic mechanisms involving abnormalities in cell signal processing occur in patients with genetically mediated TAA. (See 'Pathogenesis' above.)

The natural history of TAA is generally one of slow expansion but with an increasing risk of dissection and rupture as aortic size increases. The rate of increase in aortic diameter ranges from 0.1 to 1.0 cm per year, depending upon TAA etiology, diameter, and location within the aorta. (See 'Natural history' above and "Management of thoracic aortic aneurysm in adults", section on 'Diameter criteria'.)

ACKNOWLEDGMENTS — The UpToDate editorial staff acknowledges Christina Greene, MD, and Y Joseph Woo, MD, who contributed to an earlier version of this topic review.

The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.

  1. Pressler V, McNamara JJ. Aneurysm of the thoracic aorta. Review of 260 cases. J Thorac Cardiovasc Surg 1985; 89:50.
  2. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. Surgery 1982; 92:1103.
  3. Clouse WD, Hallett JW Jr, Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 1998; 280:1926.
  4. Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.
  5. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.
  6. Creager MA, Belkin M, Bluth EI, et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J Am Coll Cardiol 2012; 59:294.
  7. Tanaka Y, Sakata K, Sakurai Y, et al. Prevalence of Type A Acute Aortic Dissection in Patients With Out-Of-Hospital Cardiopulmonary Arrest. Am J Cardiol 2016; 117:1826.
  8. Itani Y, Watanabe S, Masuda Y, et al. Measurement of aortic diameters and detection of asymptomatic aortic aneurysms in a mass screening program using a mobile helical computed tomography unit. Heart Vessels 2002; 16:42.
  9. Kälsch H, Lehmann N, Möhlenkamp S, et al. Body-surface adjusted aortic reference diameters for improved identification of patients with thoracic aortic aneurysms: results from the population-based Heinz Nixdorf Recall study. Int J Cardiol 2013; 163:72.
  10. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55:841.
  11. Olsson C, Thelin S, Ståhle E, et al. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006; 114:2611.
  12. von Allmen RS, Anjum A, Powell JT. Incidence of descending aortic pathology and evaluation of the impact of thoracic endovascular aortic repair: a population-based study in England and Wales from 1999 to 2010. Eur J Vasc Endovasc Surg 2013; 45:154.
  13. Acosta S, Ogren M, Bengtsson H, et al. Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 2006; 44:237.
  14. Ferro CR, de Oliveira DC, Guerra Fde F, et al. Prevalence and risk factors for combined coronary artery disease and aortic aneurysm. Arq Bras Cardiol 2007; 88:40.
  15. Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm. Am Heart J 2011; 162:38.
  16. Coady MA, Davies RR, Roberts M, et al. Familial patterns of thoracic aortic aneurysms. Arch Surg 1999; 134:361.
  17. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816.
  18. Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? Circulation 1992; 85:205.
  19. Tilson MD. Aortic aneurysms and atherosclerosis. Circulation 1992; 85:378.
  20. Palmieri V, Bella JN, Arnett DK, et al. Aortic root dilatation at sinuses of valsalva and aortic regurgitation in hypertensive and normotensive subjects: The Hypertension Genetic Epidemiology Network Study . Hypertension 2001; 37:1229.
  21. Prakash SK, Pedroza C, Khalil YA, Milewicz DM. Diabetes and reduced risk for thoracic aortic aneurysms and dissections: a nationwide case-control study. J Am Heart Assoc 2012; 1.
  22. Crawford ES, Cohen ES. Aortic aneurysm: a multifocal disease. Presidential address. Arch Surg 1982; 117:1393.
  23. Agricola E, Slavich M, Tufaro V, et al. Prevalence of thoracic ascending aortic aneurysm in adult patients with known abdominal aortic aneurysm: an echocardiographic study. Int J Cardiol 2013; 168:3147.
  24. Kuzmik GA, Feldman M, Tranquilli M, et al. Concurrent intracranial and thoracic aortic aneurysms. Am J Cardiol 2010; 105:417.
  25. Ogata A, Kawashima M, Matsushima T. Behçet's disease with ruptured anterior communicating artery aneurysm following ruptured thoracic aortic aneurysm. Neurol Med Chir (Tokyo) 2013; 53:189.
  26. Schievink WI, Raissi SS, Maya MM, Velebir A. Screening for intracranial aneurysms in patients with bicuspid aortic valve. Neurology 2010; 74:1430.
  27. Lee JJ, Dimick JB, Williams DM, et al. Existence of abdominal aortic aneurysms in patients with thoracic aortic dissections. J Vasc Surg 2003; 38:671.
  28. De León Ayala IA, Chen YF. Acute aortic dissection: an update. Kaohsiung J Med Sci 2012; 28:299.
  29. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48:3522.
  30. Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 37:1539.
  31. Pacini D, Leone O, Turci S, et al. Incidence, etiology, histologic findings, and course of thoracic inflammatory aortopathies. Ann Thorac Surg 2008; 86:1518.
  32. Murzin DL, Belanger EC, Veinot JP, et al. A case series of surgically diagnosed idiopathic aortitis in a Canadian centre: a retrospective study. CMAJ Open 2017; 5:E483.
  33. Rojo-Leyva F, Ratliff NB, Cosgrove DM 3rd, Hoffman GS. Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. Arthritis Rheum 2000; 43:901.
  34. Miller DV, Isotalo PA, Weyand CM, et al. Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. Am J Surg Pathol 2006; 30:1150.
  35. Creamer TJ, Bramel EE, MacFarlane EG. Insights on the Pathogenesis of Aneurysm through the Study of Hereditary Aortopathies. Genes (Basel) 2021; 12.
  36. Chaudhry SS, Cain SA, Morgan A, et al. Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 2007; 176:355.
  37. Gallo EM, Loch DC, Habashi JP, et al. Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest 2014; 124:448.
  38. Dietz HC, Loeys B, Carta L, Ramirez F. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 2005; 139C:4.
  39. Milewicz DM, Michael K, Fisher N, et al. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation 1996; 94:2708.
  40. Milewicz DM, Chen H, Park ES, et al. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am J Cardiol 1998; 82:474.
  41. Pannu H, Fadulu VT, Chang J, et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005; 112:513.
  42. Guo D, Hasham S, Kuang SQ, et al. Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with a major locus mapping to 5q13-14. Circulation 2001; 103:2461.
  43. Vaughan CJ, Casey M, He J, et al. Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation 2001; 103:2469.
  44. Khau Van Kien P, Mathieu F, Zhu L, et al. Mapping of familial thoracic aortic aneurysm/dissection with patent ductus arteriosus to 16p12.2-p13.13. Circulation 2005; 112:200.
  45. Fletcher AJ, Syed MBJ, Aitman TJ, et al. Inherited Thoracic Aortic Disease: New Insights and Translational Targets. Circulation 2020; 141:1570.
  46. Hicks KL, Byers PH, Quiroga E, et al. Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center. J Vasc Surg 2018; 68:701.
  47. Judge DP, Dietz HC. Therapy of Marfan syndrome. Annu Rev Med 2008; 59:43.
  48. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33:407.
  49. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 1999; 340:1307.
  50. Adams JN, Trent RJ. Aortic complications of Marfan's syndrome. Lancet 1998; 352:1722.
  51. Germain DP, Herrera-Guzman Y. Vascular Ehlers-Danlos syndrome. Ann Genet 2004; 47:1.
  52. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355:788.
  53. http://www.marfan.org/marfan/2290/Loeys-Dietz-Syndrome/ http://www.ncbi.nlm.nih.gov/books/NBK1133/ (Accessed on February 06, 2012).
  54. Discovering the genetic etiologies of rare diseases in large patient collections. Nat Med 2023; 29:543.
  55. Gøtzsche CO, Krag-Olsen B, Nielsen J, et al. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch Dis Child 1994; 71:433.
  56. Ostberg JE, Brookes JA, McCarthy C, et al. A comparison of echocardiography and magnetic resonance imaging in cardiovascular screening of adults with Turner syndrome. J Clin Endocrinol Metab 2004; 89:5966.
  57. Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg 2006; 82:1400.
  58. Mongeon FP, Gurvitz MZ, Broberg CS, et al. Aortic root dilatation in adults with surgically repaired tetralogy of fallot: a multicenter cross-sectional study. Circulation 2013; 127:172.
  59. von Kodolitsch Y, Aydin MA, Koschyk DH, et al. Predictors of aneurysmal formation after surgical correction of aortic coarctation. J Am Coll Cardiol 2002; 39:617.
  60. Elsheikh M, Casadei B, Conway GS, Wass JA. Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. Clin Endocrinol (Oxf) 2001; 54:69.
  61. Kallenbach K. Editorial comment: Moderate aneuryms of the ascending aorta in stenotic bicuspid aortic valve--life threatening or merely an epiphenomenon? Eur J Cardiothorac Surg 2012; 42:838.
  62. Raunsø J, Song RJ, Vasan RS, et al. Familial Clustering of Aortic Size, Aneurysms, and Dissections in the Community. Circulation 2020; 142:920.
  63. Musunuru K. Transforming growth factor β2 mutations and familial thoracic aortic aneurysms. Circ Cardiovasc Genet 2012; 5:593.
  64. Glazer NL. Copy number variation contributes to sporadic and familial thoracic aortic aneurysms and dissections. Circ Cardiovasc Genet 2011; 4:212.
  65. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370:1920.
  66. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26:72.
  67. Nistri S, Sorbo MD, Marin M, et al. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart 1999; 82:19.
  68. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306:1104.
  69. Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44:138.
  70. Biner S, Rafique AM, Ray I, et al. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol 2009; 53:2288.
  71. Martens T, Van Herzeele I, De Ryck F, et al. Multiple aneurysms in a patient with aneurysms-osteoarthritis syndrome. Ann Thorac Surg 2013; 95:332.
  72. van der Linde D, Bekkers JA, Mattace-Raso FU, et al. Progression rate and early surgical experience in the new aggressive aneurysms-osteoarthritis syndrome. Ann Thorac Surg 2013; 95:563.
  73. van der Linde D, van de Laar IM, Bertoli-Avella AM, et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol 2012; 60:397.
  74. Cheung C, Bernardo AS, Trotter MW, et al. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat Biotechnol 2012; 30:165.
  75. Bonderman D, Gharehbaghi-Schnell E, Wollenek G, et al. Mechanisms underlying aortic dilatation in congenital aortic valve malformation. Circulation 1999; 99:2138.
  76. Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic valve: pathophysiology, molecular biology, and clinical implications. Circulation 2009; 119:880.
  77. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999; 17:615.
  78. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. Atherosclerosis 1987; 65:13.
  79. Jackson V, Olsson T, Kurtovic S, et al. Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2012; 144:459.
  80. Huusko T, Salonurmi T, Taskinen P, et al. Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysms. J Thorac Cardiovasc Surg 2013; 145:1117.
  81. Serra R, Grande R, Montemurro R, et al. The role of matrix metalloproteinases and neutrophil gelatinase-associated lipocalin in central and peripheral arterial aneurysms. Surgery 2015; 157:155.
  82. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994; 81:935.
  83. Allaire E, Hasenstab D, Kenagy RD, et al. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 1998; 98:249.
  84. Allaire E, Forough R, Clowes M, et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998; 102:1413.
  85. http://www.ncbi.nlm.nih.gov/gene (Accessed on July 10, 2013).
  86. Bee KJ, Wilkes DC, Devereux RB, et al. TGFβRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor β2 signal transduction. Circ Cardiovasc Genet 2012; 5:621.
  87. LeMaire SA, McDonald ML, Guo DC, et al. Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat Genet 2011; 43:996.
  88. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007; 39:1488.
  89. Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. J Vasc Surg 2012; 56:565.
  90. Griepp RB, Ergin MA, Galla JD, et al. Natural history of descending thoracic and thoracoabdominal aneurysms. Ann Thorac Surg 1999; 67:1927.
  91. Sueyoshi E, Sakamoto I, Hayashi K, et al. Growth rate of aortic diameter in patients with type B aortic dissection during the chronic phase. Circulation 2004; 110:II256.
  92. Hansen PA, Richards JM, Tambyraja AL, et al. Natural history of thoraco-abdominal aneurysm in high-risk patients. Eur J Vasc Endovasc Surg 2010; 39:266.
  93. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002; 73:17.
  94. Bonser RS, Pagano D, Lewis ME, et al. Clinical and patho-anatomical factors affecting expansion of thoracic aortic aneurysms. Heart 2000; 84:277.
  95. Dapunt OE, Galla JD, Sadeghi AM, et al. The natural history of thoracic aortic aneurysms. J Thorac Cardiovasc Surg 1994; 107:1323.
  96. Shang EK, Nathan DP, Sprinkle SR, et al. Peak wall stress predicts expansion rate in descending thoracic aortic aneurysms. Ann Thorac Surg 2013; 95:593.
  97. Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg 2007; 83:1338.
  98. La Canna G, Ficarra E, Tsagalau E, et al. Progression rate of ascending aortic dilation in patients with normally functioning bicuspid and tricuspid aortic valves. Am J Cardiol 2006; 98:249.
  99. Shang EK, Nathan DP, Boonn WW, et al. A modern experience with saccular aortic aneurysms. J Vasc Surg 2013; 57:84.
  100. Elefteriades JA. Indications for aortic replacement. J Thorac Cardiovasc Surg 2010; 140:S5.
  101. Pressler V, McNamara JJ. Thoracic aortic aneurysm: natural history and treatment. J Thorac Cardiovasc Surg 1980; 79:489.
  102. Crawford ES, DeNatale RW. Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease. J Vasc Surg 1986; 3:578.
  103. Kim JB, Spotnitz M, Lindsay ME, et al. Risk of Aortic Dissection in the Moderately Dilated Ascending Aorta. J Am Coll Cardiol 2016; 68:1209.
  104. Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms. Ann Thorac Surg 1997; 63:1533.
  105. Coady MA, Rizzo JA, Hammond GL, et al. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. Ann Thorac Surg 1999; 67:1922.
  106. Kim JB, Kim K, Lindsay ME, et al. Risk of rupture or dissection in descending thoracic aortic aneurysm. Circulation 2015; 132:1620.
  107. Griepp RB, Ergin MA, Lansman SL, et al. The natural history of thoracic aortic aneurysms. Semin Thorac Cardiovasc Surg 1991; 3:258.
  108. Yiu RS, Cheng SW. Natural history and risk factors for rupture of thoracic aortic arch aneurysms. J Vasc Surg 2016; 63:1189.
  109. Geisbüsch S, Stefanovic A, Schray D, et al. A prospective study of growth and rupture risk of small-to-moderate size ascending aortic aneurysms. J Thorac Cardiovasc Surg 2014; 147:68.
  110. Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 2006; 81:169.
  111. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg 1997; 113:476.
  112. Rylski B, Blanke P, Beyersdorf F, et al. How does the ascending aorta geometry change when it dissects? J Am Coll Cardiol 2014; 63:1311.
  113. Koullias G, Modak R, Tranquilli M, et al. Mechanical deterioration underlies malignant behavior of aneurysmal human ascending aorta. J Thorac Cardiovasc Surg 2005; 130:677.
  114. Ziganshin BA, Zafar MA, Elefteriades JA. Descending threshold for ascending aortic aneurysmectomy: Is it time for a "left-shift" in guidelines? J Thorac Cardiovasc Surg 2019; 157:37.
  115. Pape LA, Tsai TT, Isselbacher EM, et al. Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116:1120.
Topic 88937 Version 27.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟